Ind-Swift Laboratories Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: INDSWFTLAB BSE: 532305

₹388.75

Sept. 30, 2026 · NSE · nse_bhavcopy

Peers in Pharmaceuticals & Biotechnology

The largest companies in the same industry by market cap. This company ranks #69 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.

Company	Market cap (₹ Cr)	PE (TTM)	ROE	1Y return	Div. yield	Quality	Valuation	Momentum
Sun Pharmaceutical Industries Limited	435,863	146.5	13.7%	11.0%	—	72	8	30
Divi's Laboratories Limited	246,660	83.9	15.3%	62.7%	0.32%	70	4	51
Torrent Pharmaceuticals Limited	162,454	78.2	12.2%	34.6%	0.79%	56	0	31
Zydus Lifesciences Limited	115,910	33.3	17.3%	17.2%	0.09%	74	24	84
Cipla Limited	108,736	35.4	11.2%	-11.0%	0.97%	73	29	62
Laurus Labs Limited	106,969	122.5	17.1%	127.1%	—	78	24	53
Mankind Pharma Limited	103,406	47.4	11.7%	2.6%	—	68	12	86
Dr. Reddy's Laboratories Limited	102,916	154.7	10.9%	-0.9%	—	62	33	71
Ind-Swift Laboratories Limited (this stock)	3,381	55.4	3.0%	299.3%	—	60	36	52

Valuation multiples

Current only. Market cap is the whole company's; sales/EBITDA are trailing-twelve-month standalone; debt and cash come from the latest filed standalone balance sheet (March 31, 2026). EBITDA = PBT + interest + depreciation.

Enterprise value

₹2,983 Cr

EV / EBITDA

27.1x

EV / Sales

4.53x

Market cap / Sales

5.13x

Earnings yield

1.81%

Quarterly Financials

Download CSV

Standalone Consolidated

↑ Positive

Quarterly Revenue

Jun 2026 quarterly revenue is Rs 194 Cr, up 19.1% YoY.

Period end	Revenue (₹ Cr)	PBT (₹ Cr)	Net profit (₹ Cr)	Basic EPS
June 30, 2026	186	32	24	₹2.8100
March 31, 2026	173	12	15	₹1.7900
Dec. 31, 2025	149	18	11	₹1.3200
Sept. 30, 2025	150	11	9	₹1.1000
June 30, 2025	148	10	8	₹1.1800
March 31, 2025	145	226	218	₹32.3400
Dec. 31, 2024	1	5	5	₹0.7800
Sept. 30, 2024	3	0	0	₹0.0500
June 30, 2024	30	6	6	₹1.0500
March 31, 2024	382	483	350	₹59.1700
Dec. 31, 2023	276	26	22	₹3.6600
Sept. 30, 2023	270	36	30	₹5.0900
June 30, 2023	299	31	17	₹2.8900

Quarterly income statement (standalone, ₹ Cr)

Indicator	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23
Total income (before exceptional items)	194	175	177	168	163	149	15	16	42	407	283	278	305
Operating revenue	186	173	149	150	148	145	1	3	30	382	276	270	299
Other income	8	2	28	18	15	4	14	13	11	25	7	7	6
Operating expenses	153	148	144	148	145	105	10	15	35	286	222	207	239
Operating profit	33	25	5	2	3	40	-9	-12	-5	95	54	63	60
Operating profit margin	17.9%	14.6%	3.6%	1.5%	2.1%	27.7%	-626.0%	-443.4%	-14.9%	25.0%	19.5%	23.5%	20.0%
Depreciation	8	8	9	7	7	7	0	0	0	13	14	13	14
Interest	1	2	1	2	1	27	0	0	0	11	21	21	20
Exceptional items, gain / (loss)	-0	-5	-6	—	—	216	—	—	—	387	—	—	—
Profit before tax	32	12	18	11	10	226	5	0	6	483	26	36	31
Tax	8	-3	4	2	2	8	—	—	—	134	5	6	5
Net profit	24	—	—	9	—	218	5	0	6	350	22	30	—
EPS	2.81	1.79	1.32	1.10	1.18	32.34	0.78	0.05	1.05	59.17	3.66	5.09	2.89
Net profit (TTM)	—	—	—	—	—	229	361	378	408	—	—	—	—
EPS (TTM)	7.02	5.39	35.94	35.40	34.35	34.22	61.05	63.93	68.97	70.81	6.41	7.70	6.68

Total income excludes exceptional items, which are shown on their own row. Trendlyne and Screener fold exceptional items into revenue or other income, so their totals differ from this table by exactly that row.

Annual Financials

Year ended	Revenue (₹ Cr)	PBT (₹ Cr)	Net profit (₹ Cr)
March 31, 2026	636	50	43
March 31, 2025	550	264	256
March 31, 2024	1,227	577	418
March 31, 2023	1,152	79	42

Annual income statement (standalone, ₹ Cr; CAGR to the latest year)

Indicator	CAGR 3Y	CAGR 5Y	Mar 26	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18	Mar 17
Total income (before exceptional items)	-16.2%	-4.5%	698^†	592^†	1,273^†	1,185^†	1,030^†	880^†	781^†	762^†	750^†	—
Operating revenue	-18.0%	-5.8%	636	550	1,227	1,152	988^†	857^†	752^†	724^†	731^†	696^†
Other income	—	—	62^†	42^†	45^†	33^†	42^†	23^†	29^†	37^†	18^†	—
Operating expenses	—	—	585^†	165^†	955^†	930^†	794^†	676^†	624^†	589^†	—	504^†
Operating profit	-38.7%	-22.3%	51^†	385^†	273^†	222^†	194^†	180^†	128^†	135^†	—	192^†
Operating profit margin	—	—	8.0%^†	70.1%^†	22.2%^†	19.3%^†	19.7%^†	21.1%^†	17.0%^†	18.7%^†	—	27.5%^†
Depreciation	—	—	31^†	8^†	53^†	57^†	131^†	87^†	90^†	104^†	—	88^†
Interest	—	—	6^†	27^†	74^†	92^†	96^†	100^†	101^†	83^†	85^†	88^†
Exceptional items, gain / (loss)	—	—	-11^†	216^†	387^†	-27^†	-2^†	0^†	0^†	83^†	-1^†	-3^†
Profit before tax	-14.1%	25.5%	50	264	577	79	8^†	16^†	-34^†	68^†	29^†	-56^†
Tax	—	—	5^†	—	150^†	—	—	—	—	—	—	—
Net profit	0.1%	—	43	256	418	42	-6^†	-4^†	-35^†	48^†	18^†	-40^†
EPS	-9.2%	—	5.39^†	34.22^†	70.81^†	7.20^†	-0.96^†	-0.74^†	-7.47^†	—	—	—

^† Derived: the sum of that fiscal year's four quarterly filings (a real annual filing is used wherever one exists). Checked against filed annual figures, the sum lands within 0.5% for about 94% of company-years.

Annual ratios (standalone)

Ratio	Mar 26	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18	Mar 17
Operating margin	8.0%^†	70.1%^†	22.2%^†	19.3%^†	19.7%^†	21.1%^†	17.0%^†	18.7%^†	—	27.5%^†
EBIT margin	8.9%^†	53.1%^†	53.1%^†	14.9%^†	10.5%^†	13.6%^†	8.9%^†	20.9%^†	15.6%^†	4.6%^†
PBT margin	7.9%	48.1%	47.1%	6.9%	0.8%^†	1.9%^†	-4.5%^†	9.4%^†	3.9%^†	-8.1%^†
Net margin	6.7%	46.6%	34.1%	3.7%	-0.6%^†	-0.5%^†	-4.7%^†	6.6%^†	2.4%^†	-5.7%^†
Interest coverage	9.00x^†	10.62x^†	8.80x^†	1.86x^†	1.08x^†	1.16x^†	0.66x^†	1.82x^†	1.34x^†	0.36x^†
Dividend payout	0.0%^†	0.0%^†	0.0%^†	0.0%^†	—	—	—	—	—	—
Earnings retention	100.0%^†	100.0%^†	100.0%^†	100.0%^†	—	—	—	—	—	—
Current ratio	3.48x	3.67x	—	—	—	—	—	—	—	—
Quick ratio	2.91x	3.17x	—	—	—	—	—	—	—	—
Debt to equity	0.01x	0.03x	—	—	—	—	—	—	—	—
Return on equity	3.1%	22.0%	—	—	—	—	—	—	—	—
Return on assets	2.6%	18.0%	—	—	—	—	—	—	—	—
Return on capital employed	4.0%^†	24.2%^†	—	—	—	—	—	—	—	—
Asset turnover	0.38x	0.39x	—	—	—	—	—	—	—	—

Margins and asset turnover use operating revenue (interest earned for banks, excluding other income), not total income. Liquidity, leverage and return ratios need a filed standalone balance sheet, which exists only for recent years; returns use year-end equity/assets. Dividend payout is shown only for companies with a dividend record. † = built from a summed fiscal year.

Revenue Mix

Data unavailable.

Cash Flow

Year ended	Operating (₹ Cr)	Investing (₹ Cr)	Financing (₹ Cr)	Capex (₹ Cr)	Free Cash Flow (₹ Cr)
March 31, 2026	-40	-100	145	88	-128
March 31, 2025	-39	-110	74	64	-104
March 31, 2024	-180	-104	700	45	-224
March 31, 2023	183	-14	-168	13	169
March 31, 2022	136	3	-140	18	118

Balance Sheet (standalone)

Year ended	Total Assets (₹ Cr)	Total Equity (₹ Cr)	Reserves (₹ Cr)	Borrowings, Current (₹ Cr)	Borrowings, Non-current (₹ Cr)	Current Assets (₹ Cr)	Current Liabilities (₹ Cr)	Cash & Equivalents (₹ Cr)	Net Block (₹ Cr)	Inventory (₹ Cr)
March 31, 2026	1,654	1,371	1,284	6	12	875	252	415	275	143
March 31, 2025	1,422	1,164	1,095	15	23	794	216	413	259	107
March 31, 2024	—	—	—	—	—	—	—	—	—	—
March 31, 2023	—	—	—	—	—	—	—	—	—	—
March 31, 2022	—	—	—	—	—	—	—	—	—	—

Financial charts

Trend charts drawn from the standalone income-statement and ratio tables above (oldest year on the left); a gap means that period has no figure. Annual years marked † in the tables are derived from four quarters.